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prior to and following the switch both in the intervention and the control groups.
CONCLUSIONS:The switch to a generic substitute in the case of rosiglitazone led to
a reduction in health care costs, without affecting patients’ health.
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OBJECTIVES: Diabetes affects more than 23 million Americans. Despite the impor-
tance of drug treatment, little is known about the level of the complexity of drug
therapy and its socio-economic variants in patients with diabetes. METHODS: we
analyzed 2,189 adult patients with diabetes aged 18-85 using a nationally represen-
tative sample in Medical Expenditure Panel Survey (MEPS) in 2007, which was
linked with the prescription medication claim files. Generalized linear models
(GLMs) were used to fit the distribution of drug spending to analyze the socio-
economic variants in drug spending, controlling for age, gender, race, geographic
regions, marital status, general health perception, and 8 comorbid conditions. All
analyses were weighted to reflect the complex sample design in MEPS. RESULTS:
The 2,189 adult diabetes patients represented 17.5 million diabetes patients and a
total of $79.5 billion spending on prescription drugs by diabetes patients in the US
in 2007. On average, a diabetes patient had 46 prescriptions, for a total of $4,235 of
total drug spending and $1,323 out-of-pocket spending. The top 5 leading drug
classes included antihyperlipidemic (13.4% of total drug spending), analgesics
(4.4%), and proton pump inhibitors (3.8%), ACE-inhibitors (3.7%), and antidepres-
sants (3.2%). On average, a diabetes patient used 3.52 (s.d. 1.76) classes of drugs
within the 10 drug classes with the highest spending. In multivariate regression
analyses, compared to those enrolled in the Medicare Part D prescription drug
program, those with no health insurance, with private insurance, and Medicaid
spent 73%, 44%, and 16% less in prescription drugs (p0.001, p0.001, p0.03,
respectively). Compared to non-Hispanic whites, the blacks spent 15% less on pre-
scription drugs (p0.05). CONCLUSIONS: The diabetes patients often used a mul-
tiple classes of drugs. Insurance coverage and races affect the drug spending, hold-
ing everything else constant. More researches are much needed to investigate the
consequences of such complexity.
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OBJECTIVES: Few studies have examined the effects of the Medicare Part D cover-
age gap onmedication behaviors for diabetic patients. Diabetes accounts for 32% of
the Medicare expenditure and 20% of the Medicare beneficiaries suffer from dia-
betes. The current study examined how entering the coverage gap in 2007 affected
medication adherence rates, medication consumption behavior and resource uti-
lization among Medicare Part D beneficiaries taking oral anti-diabetic medications
with different levels of cost-sharing. METHODS: The study used a longitudinal,
retrospective pre-post cohort design with a 5% national random sample of Medi-
care enrollees. Beneficiaries on oral anti-diabetic medications entering the cover-
age gap (n78,224)were identified using prescription drug records. Health resource
utilizationmeasureswere derived from inpatient, outpatient and carrier claims for
these beneficiaries. Adherence wasmeasured as proportion of days covered (PDC).
RESULTS: A total of 60.1 % of the beneficiaries entered the coverage gap and 20.3%
reached catastrophic coverage. The number of patients who discontinuedmedica-
tions after entering the gap was associated with level of cost sharing (31.1 % (full
copayment), 20-27% (partial copayment), 14.0% (no copayment), p  0.0001). 2.0 %
of the beneficiaries switchedmedications after entering the coverage gap. However
no association of switching medications with cost sharing was observed. When
examining beneficiaries entering the gap but not reaching catastrophic coverage,
level of cost sharingwas strongly associatedwith a drop in PDC ( (5.9% decrease (no
copayment), 17% decrease (partial copayment), 20.3% decrease (full copayment),
p 0.0001). CONCLUSIONS: Increased cost sharing after entering the coverage gap
was associated with negative changes in medication consumption behaviors (ad-
herence and continuation) among patients on oral anti-diabetic medications. The
findings demonstrate the importance of efforts to fill the coverage gap in the Medi-
care Part D program in order to ensuremore appropriatemedication use behaviors,
especially for beneficiaries with partial/full cost sharing.
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OBJECTIVES: The objective of the study is to identify and measure the extent to
which gender differences in Angiotensin II Converting Enzyme Inhibitors (ACEI)
and Angiotensin Receptor Blockers (ARB) prescriptions could be explained by de-
mographic, socio-economic and health status factors. METHODS: Secondary data
analyses of merged Veteran Health Administration (VHA) and Medicare claims
data for the fiscal years 1997 through 2000. Diabetes was identified with Interna-
tional Classification of Diseases, 9th edition (ICD-9-CM) codes from inpatient or
outpatient physician visits over the 24 month period. The independent variables
were demographics, socio-economic characteristics, physical health and mental
health conditions. Based on the parameter estimates and distribution of individual
characteristics, we performed traditional and extended decomposition techniques
to analyze the drivers behind the gender differences in lipid control. Population
Studied: The final study sample consisted of 263,730 veterans who had an index
creatinine value in FY1999, and qualifying creatinine value between 90 and 365
days following. There were 5,458 women and 258,272 men veterans. RESULTS:
Overall, more men (58.1%) than women (51.3%) were prescribed ACEI/ARBs. Even
after controlling for many observable characteristics, women were less likely to
have ACEI/ARB prescriptions. The adjusted odds ratio was 0.82 with 95% CI  0.77,
0.87. Nearly one third of the 7 percentage point gap in prescription drug use was
explained by variables included in the model. The gender gap in ACEI/ARBs could
be explained by differences in indications for ACEI/ARB, diabetes severity, and
mental illness (depression, anxiety, and PTSD).CONCLUSIONS:Gender differences
in ACEI/ARB exist and only about one-third of the difference could be explained by
differences in patient characteristics. Mental health conditions may be a barrier to
lower ACEI/ARB rates among women. Our findings highlight the importance of
population health approach to medication use in terms of coordinated care for
mental illness and physical illnesses.
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OBJECTIVES: The decision to prescribe medication to newly diagnosed type 2 dia-
betic patients is influenced by subjective and objective factors including patients’
economic and social status. This study examines the relationship between social
and economic indicators and incident antidiabetic medication (ADM) prescribing
patterns. METHODS: A retrospective observational study identified newly diag-
nosed patients with type 2 diabetes from the 2007-2009 Kentucky Medicaid popu-
lation. Subjects were included if they had two diabetes-related non-complicated
claims with no claims prior to 2007 in the provider-claims file. Patients were strat-
ified into receiving an ADM 0-30 days following diagnosis and those receiving no
medicationwithin that time frame.We evaluated the effect of social and economic
factors on the pattern of prescribing. Mapping techniques were used to illustrate
county/regional ecological differences. RESULTS: Patients dispensed an ADMwere
significantly younger than those not dispensed a medication (43yo vs. 51yo;
P0.001). If patients were given an ADM, they were more likely prescribed met-
formin in the Appalachian and western rural counties compared with metropoli-
tan counties (39% vs. 32%; P0.044). Patients in urban counties were more often
dispensed insulin or two or more ADMs (44% vs. 40%; P0.136), however this was
not a significant difference. CONCLUSIONS: This study found younger patients
being prescribed an ADMwithin 30 days of incident diagnosis. Older patients were
more likely to have no medication after incident diagnosis or waiting for several
months before a medication is given. Patients in rural areas are more likely dis-
pensed metformin as the initial ADM. Multiple ADMs and insulin as the initial
medication may be a proxy measure for diabetes severity at first presentation.
PDB63
GEOGRAPHIC VARIATION IN DRUG SPENDING AND ADHERENCE PATTERNS
FOR MEDICARE BENEFICIARIES WITH DIABETES
Shoemaker JS1, Dai M2, Stuart B1
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2University of Maryland,
Baltimore, Baltimore, MD, USA
OBJECTIVES: Regional variation in healthcare spending is a long standing topic of
interest to health services research. Maturation of the Part D data affords us the
opportunity to examine this relationship with respect to drug spending and adher-
ence. Our objective is to determine if beneficiaries residing in regions characterized
by high Part D drug spending exhibit higher levels of utilization and adherence to
medications recommended in diabetes treatment guidelines. METHODS: We
tracked a random 5% sample of Medicare Part D enrollees diagnosed with diabetes
in 2006 and 2007 (N 236,321). Measures included averages for Part D spending, any
use, duration of therapy (DOT), and medication possession ratio (MPR) for oral
antidiabetic agents, ACE-inhibitors/ARBs, and antihyperlipidemic agents. We ag-
gregated individual values into metropolitan statistical areas (360) and rest-of-
state areas (48) and arrayed mean regional measures by deciles. We estimated
logistic and OLS regression models controlling for age, sex, comorbidity counts,
and decile ranking of drug spending in each beneficiary’s region of residence.
RESULTS: Part D drug spending varied by a factor of 1.89 between the lowest
($2,613) and highest ($4,952) spending deciles. After regression adjustments, the
ratio fell to 1.49.We found little geographic variation in prevalence of use andMPR.
However, DOT was roughly one month longer in each drug class in the top com-
pared to the bottom decile (p.001) in unadjusted comparisons. After adjustment,
differences in DOT range from 11-18 days longer for beneficiaries in the top spend-
ing decile (p.001). CONCLUSIONS:We found considerable geographic variation in
Part D drug spending. Almost half of the difference between the top and bottom
spending deciles could be attributed to differences in beneficiary age, sex, and
comorbidities. There were no significant regional differences in user rates or MPR,
but DOT for all three drug classes was significantly longer in high spending areas.
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OBJECTIVES: To evaluate the direct healthcare costs of type 2 diabetes (T2DM)
among older patients enrolled in Medicare Advantage plus prescription drug plan.
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